Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have received an average rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $30.00.

KYTX has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. JPMorgan Chase & Co. decreased their price target on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of institutional investors have recently bought and sold shares of KYTX. Bank of America Corp DE raised its stake in Kyverna Therapeutics by 41.6% in the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after buying an additional 6,400 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Kyverna Therapeutics by 31.1% during the first quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock valued at $132,000 after purchasing an additional 16,267 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Kyverna Therapeutics during the first quarter valued at approximately $137,000. Rhumbline Advisers increased its stake in shares of Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after purchasing an additional 5,694 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Kyverna Therapeutics during the second quarter valued at approximately $107,000. 18.08% of the stock is owned by institutional investors.

Kyverna Therapeutics Stock Performance

Shares of NASDAQ:KYTX opened at $8.63 on Thursday. The company has a market cap of $524.86 million, a price-to-earnings ratio of -2.63 and a beta of 1.95. The company has a 50-day moving average price of $8.84 and a 200-day moving average price of $8.60. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13. Kyverna Therapeutics has a 12 month low of $2.52 and a 12 month high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09. As a group, equities analysts anticipate that Kyverna Therapeutics will post -2.78 EPS for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.